Syn2Psy is an Innovative Training Network (ITN-ETN, the E standing for European) funded by the EU Horizon 2020 framework program under the Marie Sklodowska-Curie Actions (MSCA) initiative. Its mission is to provide advanced (PhD-level) training to early-stage researchers in the molecular, synaptic, circuit and behaviour basis of neuropsychiatric disorders.
The network integrates experienced researchers from top-level European research institutions (academic and from industry):
- Center for Neuroscience and Cell Biology (CNC) – University of Coimbra, Portugal
- Interdisciplinary Institute for Neuroscience (IINS) – University of Bordeaux, France
- Brain and Mind Institute (BMI) – Ecole Polytechnique Federale de Lausanne (EPFL), Switzerland
- Centre for Discovery Brain Sciences (CDBS) – University of Edinburgh, Scotland
- Centre for Neurotechnology – Imperial College London, England
- Institut de Biologie Paris-Seine (IBPS) – Sorbonne University, France
- H. Lundbeck A/S, Denmark
as well as several key partner organizations:
- Carl Zeiss Microscopy GmbH (ZEISS), Germany
- CTI Clinical Trial & Consulting Services, Portugal-USA
- Coimbra University Hospitals (CHUC), Portugal
- PIN, Portugal
- Marionet, Portugal
– Early Stage Researchers –
The recruited 14 early stage researchers (ESRs) will develop the various Syn2Psy research projects. The ESRs receive advanced training-through-research in cutting-edge topics related to synapse pathology and neuropsychiatry disorders and a broad range of key scientific and transferable skills that will ultimately make them top-level candidates for research-driven positions in the academic and non-academic sector. See projects overview >
By combining interdisciplinary and intersectoral expertise, Syn2Psy will thus prepare future leaders to address the challenges of the 21st century associated with mental healthcare research and public engagement.
Neuropsychiatric disorders represent one of the greatest medical and societal challenges of the 21st century, being the leading cause of years lived with disability worldwide. Major health policy decisions have historically been guided by disease-associated mortality, but mental disorders, associated with low mortality but high morbidity, account for a large proportion of the world’s disease burden, aggravated by the fact that few effective treatments for core symptoms are available. In order to develop better therapeutic strategies, a new mindset approach to preparing the next generation of researchers in the field must be adopted, and Syn2Psy is embracing it.